Cerebrospinal fluid and brain positron emission tomography measures of synaptic vesicle glycoprotein 2A : Biomarkers of synaptic density in Alzheimer's disease
INTRODUCTION: Positron emission tomography (PET) imaging with ligands for synaptic vesicle glycoprotein 2A (SV2A) has emerged as a promising methodology for measuring synaptic density in Alzheimer's disease (AD). We investigated associations between SV2A concentrations in the brain and cerebrospinal fluid (CSF). METHODS: Twenty-one participants with early AD and 7 cognitively normal (CN) individua
